Esperion Logo (primary).png
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
18 déc. 2024 07h00 HE | Esperion Therapeutics, Inc.
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150...
Esperion Logo (primary).png
Esperion Announces $210 Million Convertible Debt Financing
13 déc. 2024 06h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the...
Esperion Logo (primary).png
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
12 déc. 2024 08h00 HE | Esperion Therapeutics, Inc.
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing...
Esperion Logo (primary).png
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
02 déc. 2024 08h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily,...
Esperion Logo (primary).png
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
26 nov. 2024 08h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese...
Esperion Logo (primary).png
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
21 nov. 2024 08h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare...
Esperion Logo (primary).png
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
18 nov. 2024 10h30 HE | Esperion Therapeutics, Inc.
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18,...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08 nov. 2024 16h15 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs)...
Esperion Logo (primary).png
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
07 nov. 2024 06h00 HE | Esperion Therapeutics, Inc.
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New...
Esperion Logo (primary).png
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
04 nov. 2024 08h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on...